Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy
This study is currently recruiting participants.
Verified November 2012 by Areva Med LLC
Study NCT01384253   Information provided by Areva Med LLC

First Received on June 27, 2011.   Last Updated on November 1, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Neoplasms
Peritoneal Neoplasms
Ovarian Neoplasms
Pancreatic Neoplasms
Stomach Neoplasms
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Abdominal Neoplasms
Adnexal Diseases
Breast Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms by Site
Ovarian Diseases
Pancreatic Diseases
Peritoneal Diseases
Skin Diseases
Stomach Diseases
Urogenital Neoplasms
Interventions listed in this trial
²¹²Pb-TCMC-Trastuzumab
trastuzumab
Additional drug interventions recognized in this trial
Physiological Effects of Drugs
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Areva Med LLC


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services